3,3-Diethylpyrrolidine → HCID 59605879, 화합물
반응식
Br[CH2:2][C:3]1[N:4]([CH3:28])[C:5]2[C:10]([N:11]=1)=[C:9]([N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1)[N:8]=[C:7]([N:18]1[C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=3[N:20]=[C:19]1[CH3:27])[N:6]=2.[CH2:29]([C:31]1([CH2:36][CH3:37])[CH2:35][CH2:34][NH:33][CH2:32]1)[CH3:30]>>[CH2:29]([C:31]1([CH2:36][CH3:37])[CH2:35][CH2:34][N:33]([CH2:2][C:3]2[N:4]([CH3:28])[C:5]3[C:10]([N:11]=2)=[C:9]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[N:8]=[C:7]([N:18]2[C:22]4[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=4[N:20]=[C:19]2[CH3:27])[N:6]=3)[CH2:32]1)[CH3:30]참가 물질
3
실험 절차
4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 3,3-diethylpyrrolidine via General Procedure E to give 26.5 mg of 301 following reverse phase purification. MS (Q1) 4892 (M)+
후처리
- customto give
- custom26.5 mg of 301 following reverse phase purification
출처 및 근거
- ORD 기록
- ord-fd14650049e64d279e0c3173ec202437